All About Santhara, Jain Ritual Of Voluntary Fasting To Death
A three-year-old girl suffering from a terminal illness died after being administered Santhara – a Jain ritual of voluntary fasting unto death – by a spiritual leader in Indore.
Viyana Jain, daughter of IT professionals Piyush and Varsha Jain, was diagnosed with brain tumour last December. After surgery and treatment failed, the family turned to spiritual guidance. On March 21, during a visit to Jain monk Rajesh Muni Maharaj, the child was given the Santhara vow with her parents' consent. Minutes later, she died.
What Is Santhara?
Santhara, also known as Sallekhana, is a Jain religious practice in which an individual voluntarily chooses to end their life through fasting, according to A Sundara, head of the Department of Archaeology and Museums in Karnataka. The practice involves gradually abstaining from food and water, and is undertaken by Jains as a way to purify the soul and attain liberation.
The vow cannot be taken at will.
According to A Sundara's research, Jain scriptures clearly say that Santhara should only be observed when death is near, or when a person is unable to follow religious duties due to old age, incurable illness, or extreme conditions like famine.
For example, if someone's worsening eyesight leads them to unknowingly harm living beings – violating the principle of ahimsa – they may choose Santhara.
The Practice Of Santhara
An important Jain text from around the 4th century AD, Ratnakaranda Shravakachara by Samantabhadra, gives a clear explanation of the Santhara vow and how it should be followed.
The text says that this vow should be taken to free the soul from the body, but only during extreme situations – like a natural disaster, old age, or an illness that cannot be cured.
Anyone taking the vow must control their emotions, give up all their possessions, and mentally detach from loved ones. They should forgive everyone, ask for forgiveness, and feel sorry for their wrongdoings. Then, with a peaceful mind, they should focus on prayers and slowly stop eating and drinking and fast until death.
Is Santhara Legal?
While Santhara is an accepted and revered practice in Jainism, it has faced legal challenges in India. In 2015, the Rajasthan High Court ruled that Santhara should be considered illegal, equating it to suicide under Section 306 of the Indian Penal Code (IPC). The court's reasoning was that the voluntary decision to end one's life was a form of self-harm and could not be justified as a religious practice.
The ruling, however, was met with protests from the Jain community. A month later, the Supreme Court stayed the order, allowing Santhara to continue under religious freedom protections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
14 hours ago
- Indian Express
High costs of life-saving drugs leave patients of rare diseases in the lurch: Will their crusade for Indian variants win?
For Seba P A, 26, from Kerala, the cost of breathing easy, moving around and enduring fewer bouts of infection comes at a steep price — nearly Rs 18 lakh per month. For long, she had managed with the Rs 50 lakh government grant under the national policy of rare diseases, one of which — Spinal Muscular Atrophy — she is battling. Now she is on a crusade to make life-saving drugs, currently under patents, affordable for persons suffering from rare diseases. Suffering from Spinal Muscular Atrophy (SMA), a rare disease that progressively affects muscle functions, her condition can be managed with Risdiplam. Developed by Swiss pharma giant Roche, one bottle of Risdiplam costs around Rs 6 lakh in India — something her taxi driver father cannot afford. In a bid to make the life-altering medicine affordable for SMA patients like herself, Seba had in December 2023 filed a petition in the Kerala High Court urging the government to invoke the compulsory licensing clause under Section 84 of the Indian Patents Act, 1970. This allows the Indian government to grant someone other than the patent holder the right to make the medicine if a product or process is nationally unavailable or overpriced. Roche holds the patent for Risdiplam till May 2035. Her case is now being heard in the Supreme Court. 'If other companies start manufacturing the drug, the prices are likely to plummet,' says Seba. Like her, patients suffering from rare diseases, who need life-long therapy, have been urging the government to invoke the compulsory licensing clause. WHY PATIENTS OF RARE DISEASES RAN OUT OF OPTIONS Two years ago, Seba's family had applied for financial aid under the Centre's National Policy for Rare Diseases, 2021, which had identified 1,000 patients, including Seba, for a one-time financial assistance of Rs 50 lakh each. 'When I was taking Risdiplam, my health was stable. I was able to speak and sing. However, the funds got exhausted in mid-February. Since then, I have already had two bouts of infections and have been confined to bed,' Seba, who loves singing and painting, tells The Indian Express. Though she is back on Risdiplam, being provided by Roche free of cost for a year while the case is on, it continues to be out of reach to other SMA patients. The mother of a 14-year-old boy from Bengaluru has been struggling to obtain medicine to treat his cystic fibrosis (CF), a genetic condition that affects cells that produce mucus, sweat and digestive juices, making them thick and sticky, clogging up lungs and the digestive system. In 2019, Trikafta, a three-drug combination sold by US-based Vertex, was approved by the US Food and Drug Administration (FDA) for CF treatment. 'Importing a three-month supply costs Rs 70 lakh. An Argentina company manufactures a slightly cheaper version that costs around Rs 21 lakh for a three-month supply,' she says. She is one of the petitioners urging the government to grant a compulsory license for the medicine. In an attempt to get the medicine from Argentina, the mother scours Facebook for Indians living there and requests them to get the medicine when they come home. 'I split the tablets to make them last at least six months. If Indian companies are given compulsory licences, I might be able to afford medicines for my son,' she says. WHAT'S THE STATUS OF COMPULSORY LICENSING CLAUSE? Despite the exorbitant cost of drugs used to manage rare diseases, India's compulsory licensing clause has been used just once in 20 years. 'Only one private company got a compulsory license once,' says Anand Grover, a senior lawyer who works on such patent cases, referring to the New Delhi-based Natco Pharma, which secured the permit to manufacture Nexavar, a cancer drug made by German multinational Bayer, in 2012. Since then, three Indian companies have unsuccessfully applied for compulsory licences — BDR Pharmaceuticals for Dasatinib (for leukemia), Lee Pharma for Sitagliptin (for diabetes), and Emcure Pharmaceuticals for Trastuzumab (for breast cancer), says Sneha Sharma, a partner at Sujata Chaudhri IP Attorneys. ROCHE VS NATCO In 2024, Roche Pharmaceuticals had filed a petition to get an injunction, claiming that Natco Pharmaceutical was in the process of launching a generic version of Risdiplam. Though its injunction was denied by the Delhi High Court in March 2025, the Swiss drug-maker has filed an appeal. The Division Bench has heard the arguments in the case and is now awaiting written statements from both parties. Meanwhile, Natco announced that if it is allowed to manufacture and market the generic version of Risdiplam, it will sell it for just Rs 15,900 per bottle (against Roche's Rs 6 lakh per bottle). Though Roche's assistance programme provides five bottles at the cost of two, patients still end up spending nearly Rs 30 lakh annually. A generic version of Risdiplam would mean that the government's Rs 50-lakh aid will last almost nine years instead of just a few months for SMA patients. Risdiplam is sold for around $500 (around Rs 42,000) per bottle in China and Pakistan. 'Risdiplam costs less in China and Pakistan where prices were negotiated with the company. Since that did not happen in India, a simple solution would be to issue a compulsory license to Natco,' says Grover. He also challenged the narrative put forth by the Swiss drug-maker, which said that a drug's exorbitant prices were meant to cover the 'high costs' of research and development (R & D). In its suit against Natco, Roche had said that it takes a company nearly 10-15 years and an estimated $2.6 billion (nearly Rs 260 crore) to bring a successful drug to the market. The company had claimed that only one in nearly 5,000 or 10,000 drugs in the research pipeline and around 12% of those in clinical trials get approved. 'Many drugs are, in fact, developed by smaller companies that are acquired by bigger ones and taken to clinical trials. Big companies often hold these patents despite not bearing initial costs of developing several candidate drugs. The figures these companies have been giving out for years are an exaggeration. Which is why we ask for actual costs the companies incur on drug R & D,' says Grover. He says studies have shown that the cost of developing Risdiplam would, at most, be $150 million, a figure that has not yet been contested by the company. HOW PHARMA MAJORS PROLONG PATENT CONTROL Pharma giants find loopholes to prolong their control over a drug. When it comes to Trikafta, the CF drug, Vertex Pharmaceuticals already holds the patent for two of these medicines in India while an application for the third is in process. 'In a blatant abuse of its monopoly, Vertex has filed and obtained multiple patents in India, thus having monopoly rights on various CFTR modulators (a class of medications designed for individuals with CF). But it has not bothered to register the medicine in India,' states a 2024 petition by CF patients in the Karnataka High Court. Sharma says a compulsory licence may also be issued if a patent holder has not worked the patent in over three years. PATENTING PHARMACEUTICALS IN INDIA When the country's new patent law was brought out in the 1970s, the government created a very important provision — it allowed for only process patenting when it came to pharmaceuticals. 'After the British left, drugs in India were very costly. A committee set up by (then PM) Mrs (Indira) Gandhi recommended dropping product patenting for pharmaceuticals. If a product is patented, you cannot do anything. But if a process is patented, you can legally make a similar drug using another process. That is what was done under the new Patent Act that came into force in 1972,' says Grover. This decision was key to the generic manufacturing of pharmaceuticals in India, earning the country the moniker of the 'pharmacy of the world.' Meanwhile, the US, which wanted to create a monopoly for itself, forced the world to accept the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which came into effect on January 1, 1995. While countries like Brazil, Mexico and India initially formed a block against TRIPS, threats of sanctions forced them to toe the line. India was given time till 2005 to implement provisions similar to the ones in the US — ensuring product patents and extending patent period from seven to 20 years, explains Grover. In fact, India's Patent Act, which allowed only the process to be patented, became the reason why Indian drug-maker Cipla could establish itself as the 'Robin Hood' of pharmaceuticals. In 2001, the company started selling a cocktail of antiretrovirals (medicines used to manage HIV) for less than $1 a day, driving down the prices of the medication across the world. Grover says, '(Despite TRIPS), we still tried to maintain some provisions that would help our people. Our law does not allow extending patents simply by changing the medicine's form or replacing some salts (a process called ever-greening of patents) unless there is a significant change in its efficacy. Our law also allows for both pre and post-grant opposition.' Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Time of India
3 days ago
- Time of India
HC grants conditional release of documents for PG medical students
Jaipur: Rajasthan High Court Friday provided relief to MBBS graduates pursuing post-graduate studies and directed SMS Medical College and other medical institutions to return their original documents in a case regarding post-PG senior residency internship. The court stipulated that petitioners must provide an undertaking to the state govt, agreeing to pay Rs 10 lakhs if they do not complete their senior residency. While hearing over two hundred petitions, including one by Dr Syed Shabaz and others, Justice Sameer Jain dismissed the state govt's review petition on grounds that the matter is already being heard by a division bench. "We have maintained that govt wants them to serve in govt hospital for 2 years after completing post-graduation," stated Archit Bohra, additional govt counsel. Petitioners explained that during PG course admission, applicant are required to sign a Rs 10 lakh bond, promising to serve the state govt for two years post-course, or pay the bond amount of Rs 10 lakh. Petitioners, however, challenged the govt's decision. TNN Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Time of India
3 days ago
- Time of India
IMA seeks clarity on emergency scheme for road accident victims in Haryana
Gurgaon: Indian Medical Association (IMA)'s Haryana chapter on Friday sought immediate clarification about the cashless treatment pertaining to road accident victims. In fact, private hospitals, which have been roped in, are flagging a lack of clarity on operational guidelines, payment mechanisms and treatment rates. The development comes against the backdrop of a statewide rollout of Haryana's cashless treatment scheme for road accident victims, which has been facing serious roadblocks. The scheme, aimed at ensuring free emergency care for accident victims during the crucial first seven days or up to Rs 1.5 lakh, was earlier restricted to Ayushman Bharat-empanelled hospitals. However, with limited participation due to extremely low reimbursement rates and infrastructure constraints, directorate general of health services (DGHS), Haryana, issued fresh instructions on June 4 to onboard non-Ayushman hospitals as well. In a letter addressed to DGHS, IMA has sought guidelines on how the new hospitals will be empanelled, which portal will be used to register and track patients and how payments will be made. IMA has requested DGHS to immediately issue a detailed guideline outlining onboarding steps, financial coverage, payment timelines and rate revisions to ensure that hospitals can realistically provide care without suffering financial losses. IMA Haryana president Dr Mahaveer P Jain told TOI, 'There is no clarity on who will pay for these services, how the bills will be submitted or processed, or what rates will be given for ICUs, surgeries or diagnostic tests.' 'Without this, the scheme will collapse before it starts,' Jain said. IMA has also flagged the Ayushman Bharat rates — under which hospitals are expected to provide comprehensive trauma care at around Rs 1,000 per day, including medicines, ICU care and CT/MRI scans — as completely unviable. 'This was the main reason the scheme failed to take off earlier in Haryana,' former IMA president Dr Ajay Mahajan said. 'The state is now asking more hospitals to join, but without fixing the fundamental flaws,' Mahajan said. The recent directive by DGHS to involve other hospitals is seen as an attempt to revive the programme. But without a standard operating procedure (SOP), notification system for hospitals, or clear reimbursement policy, medical professionals say it's set up for another failure. 'Unless the state addresses these gaps swiftly, it's just another policy on paper. Meanwhile, lives that could have been saved continue to be lost,' Dr IMA Haryana secretary Dhirendar K Soni said. A senior official from DGHS (Haryana) said, 'The objective is to ensure no road accident victim is denied emergency care due to lack of financial resources. We are actively working on streamlining the onboarding process for non-Ayushman hospitals and will soon issue clear SOPs, including case registration protocols and payment mechanisms.' Additional chief secretary, health and family welfare, Sudhir Rajpal on June 4 chaired a review meeting on the implementation of the scheme aimed at providing free and cashless emergency medical treatment to road accident victims across the state. During the meeting, it was informed that all hospitals empanelled under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) are by default automatically included under the road accident treatment scheme. However, it was highlighted that a greater number of hospitals need to be brought on board to ensure that accident victims receive timely and quality care at the nearest available health facility. The scheme showed promising results during a pilot project conducted at IIT Chennai, where full govt funding for the first week of post-accident treatment helped significantly reduce fatalities. Inspired by this, the Centre rolled it out in five states — including Haryana — under the condition that only Ayushman-empanelled hospitals would be included. However, this restriction, combined with low package rates, limited the scheme's effectiveness. As traffic accident numbers continue to rise, healthcare professionals warn that any further delay in resolving these issues could prove fatal — not just for victims on the road, but for the credibility of the state's emergency healthcare initiatives. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
